Shares of Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Get Free Report) were down 0.6% during trading on Monday . The stock traded as low as $64.70 and last traded at $64.70. Approximately 1 shares changed hands during trading, The stock had previously closed at $65.10.
Basilea Pharmaceutica Stock Performance
The company has a current ratio of 5.11, a quick ratio of 4.68 and a debt-to-equity ratio of 0.59. The firm has a 50-day simple moving average of $61.42 and a two-hundred day simple moving average of $67.01.
About Basilea Pharmaceutica
Basilea Pharmaceutica AG is a Swiss biopharmaceutical company headquartered in Basel, specializing in the development and commercialization of innovative treatments for hospital‐treated diseases. The company’s research is focused primarily on anti‐infectives and oncology, with a portfolio that spans both marketed products and early‐ to late‐stage pipeline candidates. Basilea leverages medicinal chemistry expertise to address critical medical needs in fungal infections, bacterial infections and cancer.
Among its lead products is isavuconazole, a broad‐spectrum antifungal agent marketed under the trade name Cresemba.
Featured Stories
- Five stocks we like better than Basilea Pharmaceutica
- SpaceX: Love the Company, But the Stock Is a Harder Call
- Ulta’s Growth Is Real, But So Are the Risks
- BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
- Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
